Literature DB >> 2938524

High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications.

T L Yaksh, G J Harty, B M Onofrio.   

Abstract

In rats with chronically implanted intrathecal catheters, high concentrations of morphine (3 microliters of 50 mg/ml: 150 micrograms) yielded a reliable and striking syndrome of pain behavior that involved intermittent bouts of biting and scratching at the dermatomes innervated by levels of the spinal cord proximal to the catheter tip. In addition, during intervals between bouts of agitation, the animals displayed a clear, marked hyperesthesia where an otherwise innocuous stimuli (brush stroke) evoked significant signs of discomfort and consequent aggressive behavior. These effects were exaggerated rather than reversed by high doses of naltrexone. The effect, perfectly mimicked by a considerably lower dose of morphine-3-glucuronide (15 micrograms) or the glycine antagonist strychnine (30 micrograms), was not produced by equimolar concentrations of sodium sulfate, glucuronide, methadone, or sufentanil. In halothane-anesthetized cats, light brushing of the hindpaw and tail or low-intensity stimulation of the sciatic nerves resulted in prominent elevations in blood pressure and pupil diameter following the intrathecal administration of high concentrations (50 mg/ml; 0.1 ml) of morphine sulfate. This effect, exaggerated by naloxone, was produced by a lower concentration of intrathecal morphine-3-glucuronide (5 mg/ml; 0.1 ml) but not by intrathecal saline. These results suggest the possibility that the effects of high doses of morphine may be characterized by a nonopiate receptor-mediated effect that alters the coding of sensory information in the spinal cord. The authors speculate that high concentrations of spinal opiates, as may be employed in tolerant terminal-cancer patients, could exert an action that physiologically antagonizes the analgesic effects otherwise mediated by the action of morphine on the spinal opiate receptor.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2938524     DOI: 10.1097/00000542-198605000-00008

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  35 in total

Review 1.  Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis.

Authors:  Andrew J Dowson; David W Dodick; Volker Limmroth
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

Review 3.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Subarachnoid Techniques for Cancer Pain Therapy: When, Why, and How?

Authors: 
Journal:  Curr Rev Pain       Date:  1999

5.  Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance.

Authors:  T W Vanderah; L R Gardell; S E Burgess; M Ibrahim; A Dogrul; C M Zhong; E T Zhang; T P Malan; M H Ossipov; J Lai; F Porreca
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

Review 6.  Sufentanil. A review of its pharmacological properties and therapeutic use.

Authors:  J P Monk; R Beresford; A Ward
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

7.  Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates.

Authors:  Jeroen W B Peters; Brian J Anderson; Sinno H P Simons; Donald R A Uges; Dick Tibboel
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 8.  Pathophysiology and management of opioid-induced pruritus.

Authors:  Arjunan Ganesh; Lynne G Maxwell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Reduced cold pain tolerance in chronic pain patients following opioid detoxification.

Authors:  Jarred Younger; Peter Barelka; Ian Carroll; Kim Kaplan; Larry Chu; Ravi Prasad; Ray Gaeta; Sean Mackey
Journal:  Pain Med       Date:  2008-06-18       Impact factor: 3.750

10.  Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta.

Authors:  S S Lewis; M R Hutchinson; N Rezvani; L C Loram; Y Zhang; S F Maier; K C Rice; L R Watkins
Journal:  Neuroscience       Date:  2010-01-20       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.